ValiRx PLC Proposed Appointment of Non-Executive Director (3475Y)

TIDMVAL

RNS Number : 3475Y

ValiRx PLC

06 September 2022

6 September 2022

ValiRx PLC ("ValiRx" or the "Company")

Proposed Appointment of Non-Executive Director

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health is pleased to announce that, subject to standard regulatory due diligence, it intends to appoint Stella Panu as a Non-Executive Director of the Company.

Stella has extensive experience as an investment management specialist with a particular interest in life sciences.

Dr Kevin Cox, Chair ValiRx PLC, commented "Stella will be an invaluable addition to the Board, providing help and advice on a number of fronts, especially in progressing our intended strategy. I am delighted that she shares our vision for ValiRx and look forward to working with her".

Dr Suzy Dilly, CEO of ValiRx PLC commented "I'm delighted to start working with Stella, drawing on her vast commercial experience in deal making, to support both our licencing and M&A activities. As the first in our intended series of appointments, I'm excited by the prospect of expanding the breadth and depth of commercial expertise within the Company".

*** ENDS ***

For more information, please contact:

 
 ValiRx plc                                        Tel: [phone] 
                                                    www.valirx.com 
  Dr Suzanne Dilly, CEO                             [e-mail] 
 
  Dr Adam Hargreaves, Shareholder Representative    [e-mail] 
 V Formation (Public Relations)                    [phone] 
                                                    www.vformation.biz 
  Lucy Wharton - Senior PR Executive 
  Sue Carr - Director                               [e-mail] 
                                                    [e-mail] 
                                                  ---------------------------------- 
 Cairn Financial Advisers LLP (Nominated           Tel: [phone] 
  Adviser)                                          0880 
 
  Liam Murray/Jo Turner/Ludovico Lazzaretti 
                                                  ---------------------------------- 
 Cenkos Securities Limited (Joint                  Tel: [phone] 
  Broker)                                           8900 
 
  Russell Kerr/Michael Johnson (Sales) 
 
  Callum Davidson/Giles Balleny (Corporate 
  Finance) 
                                                  ---------------------------------- 
 Turner Pope Investments (Joint Broker)            Tel: [phone] 
  James Pope / Andy Thacker                         0050 
                                                  ---------------------------------- 
 

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary

companies for further clinical development and commercialisation.   https://www.valirx.com/ 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBCGDCLXGDGDU

(END) Dow Jones Newswires

September 06, 2022 02:15 ET (06:15 GMT)